Press Releases Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 05:00:50 2026-01-16 am EST			5-day change	1st Jan Change
1,175.55 ^INR	-0.92%		-2.65%	-7.51%

10:42am	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up Over 2% for Week	MT
Jan. 14	Dr. Reddy's Laboratories Ltd. Announces the Launch of Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%	CI

Press Releases

Jan. 15	Dr. Reddy's announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S.	AQ
Jan. 14	Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.	BU
Jan. 14	Dr Reddy Laboratories : . Reddy’s announces the first-to-market launch of Olopatadine Hyochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.	PU
Jan. 06	Dr Reddy Laboratories : . Reddy's launches Hevaxin®, a novel recombinant Hepatitis E vaccine in India	PU
Dec. 02	Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies	BU
Dec. 02	Dr Reddy Laboratories : PBS listing for Zytorvi®* (toripalimab), the first and only immunotherapy for a rare type of head and neck cancer	PU
Nov. 24	Dr Reddy Laboratories : . Reddy’s receives European Commission Approval for AVT03 (denosumab), a Proposed Biosimilar of Prolia® and Xgeva®	PU
25-10-30	Dr Reddy Laboratories : CORPORATE GOVERNANCE REPORT	PU
25-10-24	Dr Reddy Laboratories : INDAS Consolidated Q2 FY 2025-26	PU
25-10-24	Dr Reddy Laboratories : INDAS Standalone Q2 FY 2025-26	PU
25-10-24	Doctor Reddy's: Fiscal Q2 Earnings Snapshot	AQ
25-10-24	Dr Reddy Laboratories : . Reddy’s Q2 & H1FY26 Financial Results	PU
25-10-22	Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025	BU
25-09-25	Dr Reddy Laboratories : Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs	PU
25-09-23	Dr Reddy Laboratories : . Reddy’s receives positive CHMP opinion from European Medicines Agency for AVT03 (denosumab), a Proposed Biosimilar of Prolia® and Xgeva®	PU
25-09-20	Dr Reddy Laboratories : CDP Corporate Response (CDP Corporate Response 2025 0)	PU
25-09-16	Dr Reddy Laboratories : . Reddy's launches novel molecule ‘Tegoprazan’ in India.	PU
25-08-26	Dr Reddy Laboratories : . Reddy's launches Linaclotide (Colozo®) a novel ug for Chronic Constipation management in adults, in India.	PU
25-08-19	Dr Reddy Laboratories : 10067-Water Stewardship Policy A3 Artwork	PU
25-08-13	Dr Reddy Laboratories : DNV GHG Verification Statement FY24-25 Signed	PU
25-08-05	Dr Reddy Laboratories : Tax Transparency Report FY 2024-25	PU
25-08-04	Dr. Reddy's Reports Record Revenues in Q1, Signals Steady Execution Through Transition Year	AQ
25-07-29	Dr Reddy Laboratories : DRL Q1FY26 Earnings Call Transcript 23Jul2025 upload	PU
25-07-29	Dr Reddy Laboratories : Corporate Governance Report- June 2025	PU
25-07-29	Dr Reddy Laboratories : FTO-09 ISO-45001 Valid till 4th April 28	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Dr. Reddy's Laboratories Ltd: Toripalimab drug launched in India

December 17, 2024 at 09:45 am EST